Liaoning Cheng Da Co., Ltd. Class A

Liaoning Cheng Da Co., Ltd. Class A

SSSE:600739
9.78
CNY
0.00
(0.00%)
0.74EPS
9.90P/E
15.54BMarket Cap
Liaoning Cheng Da Co., Ltd. Class A
SSE:600739
(Shanghai Stock Exchange)

Recent

price

9.78

P/E

ratio

9.90

div

yld

4.76%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
5.81
7.07
7.56
7.58
6.59
6.04
5.72
9.15
12.58
11.64
11.07
12
9.21
6.63
7.2
6.45
5.61
Revenue per Share
1.39
1.65
0.51
0.62
0.58
0.34
0.62
0.95
0.5
0.78
1.81
1.41
0.8
0.15
0.14
0.48
1.03
Basic EPS, GAAP
-0.34
-0.38
-0.75
-0.71
-0.6
-0.08
0.22
-0.49
-0.01
0.08
0.29
-0.2
0.51
-0.38
0.1
- -
- -
Free Cash Flow per Basic Share
0.05
0.11
0.05
0.08
0.13
0.32
0.33
0.33
0.51
0.34
0.47
0.64
0.66
0.58
0.53
0.4
0.47
Dividend per Share
5.56
7.05
7.59
8.49
9.41
11.4
12.13
13.09
13.28
14.1
15.73
18.3
18.77
18.82
19.15
18.82
20.11
Book Value per Share
5.32
6.71
7.18
7.52
8.52
10.69
11.46
12.44
12.6
13.78
15.47
18
18.38
18.35
18.56
18.29
19.57
Tangible Book Value per Share
903
1,366
1,363
1,364
1,402
1,513
1,530
1,530
1,533
1,524
1,531
1,531
1,529
1,554
1,497
1,534
1,524
Basic Weighted Avg Shares
5,245
9,664
10,294
10,334
9,239
9,140
8,750
13,999
19,275
17,746
16,945
18,373
14,089
10,305
10,770
9,902
8,547
Sales/Revenue/Turnover
9.53
7.53
5.78
3.58
4.67
3.37
4.06
3.62
3.37
4.33
5.99
5.6
9.72
5.37
1.57
-0.86
0.04
Operating Margin (%)
76
82
151
189
206
394
300
288
37
366
378
371
380
355
367
362
- -
Depreciation Expense
1,259
2,254
695
846
813
515
948
1,446
766
1,189
2,771
2,159
1,224
233
210
737
1,572
Net Income, GAAP
6.83
19.38
12.58
13.16
8.39
20.02
12.36
8.17
13.16
10.53
6.87
5.52
15.16
111.13
10.19
18.21
5.12
Effective Tax Rate (%)
24
23.32
6.75
8.18
8.8
5.63
10.83
10.33
3.98
6.7
16.35
11.75
8.68
2.26
1.95
7.44
18.39
Profit Margin (%)
1,326
1,585
357
952
1,989
1,389
-6,006
-4,581
-3,501
-1,745
-2,838
177
2,324
-276
84
2,415
3,352
Working Capital
550
570
49
1,300
2,366
1,000
1,000
2,548
3,500
5,550
4,226
2,553
4,481
3,326
4,193
7,345
7,908
LT Debt
8,069
10,262
11,051
12,993
14,890
18,687
20,004
21,347
21,664
22,939
25,006
31,477
32,228
31,623
32,383
32,477
34,308
Total Equity
17.01
24.23
7.17
7.28
5.74
6.33
5.04
6.18
2.96
4.13
6.45
6.45
3.35
-0.04
1.52
0.77
- -
Return on Invested Capital (%)
13.8
20.64
5.33
5.65
4.48
3.57
5.18
6.58
3.98
5.04
10.61
6.33
3.54
0.91
0.8
3.67
- -
Return on Capital (%)
17.89
26.22
6.96
7.71
6.49
3.33
5.27
7.49
3.8
5.68
12.15
8.3
4.32
0.81
0.72
2.54
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
5,659
6,709
6,982
LT Borrowings
8,506
7,518
7,898
LT Finance Leases
8
6
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,530
1,522
1,522
Market Capitalization
17,194
15,391
15,543

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
11,764
12,486
12,484
Cash, Cash Equivalents & STI
8,308
8,396
8,843
Accounts Receivable, Net
1,714
2,002
1,717
Inventories
1,136
838
884
Total Current Liabilities
8,400
9,781
9,132
Payables & Accruals
- -
- -
- -
ST Debt
5,659
6,709
6,982
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.92%
5.82%
0.29%
Free Cash Flow
-238.11%
-186.22%
-102.09%
Net Income, GAAP
37.3%
19%
251.48%
Sales/Revenue/Turnover
3.57%
-9.06%
-8.06%
Total Cash Common Dividend
5.96%
-1.32%
-21.54%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,340
2,932
2,889
2,488
10,770
2025
2,461
2,642
2,629
2,169
9,902
2026
1,991
2,420
1,966
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.24
0.17
-0.33
0.14
2025
0.23
0.24
- -
-0.41
0.48
2026
0.36
0.7
0.38
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.15
0.21
0.09
0.53
2025
0.05
0.11
- -
0.09
0.4
2026
0.05
0.09
0.24
- -
- -
Business
Liaoning Cheng Da Co., Ltd. (600739.SS) is a diversified state-owned conglomerate primarily engaged in supply chain trade, biopharmaceuticals, financial investment, and energy development; its core products and services encompass import and export trading of textiles, garments, bulk commodities including coal, steel, aquatic and agricultural products; biological vaccines such as rabies vaccines for human use and research into bivalent hemorrhagic fever with renal syndrome vaccines, meningococcal polysaccharide conjugate vaccines, tetravalent influenza virus split vaccines, Haemophilus influenzae type B conjugate vaccines, and inactivated hepatitis A vaccines; financial services through investments in securities, insurance, funds, and enterprises like GF Securities and China Insurance; energy projects involving shale oil mining, production, and sales; as well as pharmacy chain operations, property leasing, warehousing, and retail distribution of consumer goods such as chemical products, edible oils, electronic products, construction materials, and health products. The company operates across China and internationally in regions including the Americas, Africa, Europe, Oceania, and Asia, with subsidiaries and affiliates such as Liaoning Chengda Biotechnology Co., Ltd., Liaoning Chengda International Trade Co., Ltd., Xinjiang Chengda Baoming Energy Co., Ltd., and Chengda Fangyuan Pharmaceutical Chain Investment Co., Ltd.; it targets diverse customer segments from international trade partners and healthcare providers to financial institutions and energy consumers. Founded in 1991 as Liaoning Province Needle Cotton Wool Fabric Import and Export Company and headquartered at Chengda Building, No. 71 Renmin Road, Dalian, Liaoning Province, China, the company restructured into its current form in 1993 and listed on the Shanghai Stock Exchange in 1996. In recent developments, Liaoning Cheng Da completed the issuance of RMB 1.8 billion in exchangeable corporate bonds and plans a non-public issuance of up to RMB 5 billion in exchangeable CSI Enterprise bonds; its subsidiary Chengda Biotech signed a 2025 cooperation agreement with Zhongke Zidong Taichu (Beijing) Technology Co., Ltd. to establish an AI+ Vaccine Research and Development Joint Laboratory, focusing on data integration, technical research, service empowerment, and ecological construction; Gortune Investment obtained controlling interest through a board election on February 28, 2025, holding 15.30% of shares; and Shaoguan Gaoteng Enterprise Management Co., Ltd. proposed acquiring a 44.2% stake in Liaoning Chengda Biotechnology Co., Ltd. for CNY 4.7 billion.